Case report: Mitochondrial trifunctional protein deficiency caused by

CNS demyelination MTP deficiency brain calcification cerebral gadolinium enhancement higher brain dysfunction peripheral neuropathy

Journal

Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899

Informations de publication

Date de publication:
2023
Historique:
received: 16 03 2023
accepted: 23 05 2023
medline: 30 6 2023
pubmed: 30 6 2023
entrez: 30 6 2023
Statut: epublish

Résumé

Mitochondrial trifunctional protein (MTP) deficiency is an autosomal recessive disorder caused by impaired metabolism of long-chain fatty acids (LCFAs). Childhood and late-onset MTP deficiency is characterized by myopathy/rhabdomyolysis and peripheral neuropathy; however, the features are unclear. A 44-year-old woman was clinically diagnosed with Charcot-Marie-Tooth disease at 3 years of age due to gait disturbance. Her activity and voluntary speech gradually decreased in her 40s. Cognitive function was evaluated and brain imaging tests were performed. The Mini-Mental State Examination and frontal assessment battery scores were 25/30 and 10/18, respectively, suggesting higher brain dysfunction. Peripheral nerve conduction studies revealed axonal impairments. Brain computed tomography showed significant calcification. Magnetic resonance imaging revealed an increased gadolinium contrast-enhanced signal in the white matter, suggesting demyelination of the central nervous system (CNS) due to LCFAs. The diagnosis of MTP deficiency was confirmed through genetic examination. Administration of L-carnitine and a medium-chain fatty triglyceride diet was initiated, and the progression of higher brain dysfunction was retarded within 1 year. This patient's presentation was suggestive of CNS demyelination. The presence of brain calcification, higher brain dysfunction, or gadolinium enhancement in the white matter in patients with peripheral neuropathy may be suggestive of MTP deficiency.

Identifiants

pubmed: 37388542
doi: 10.3389/fneur.2023.1187822
pmc: PMC10299898
doi:

Types de publication

Case Reports

Langues

eng

Pagination

1187822

Informations de copyright

Copyright © 2023 Ishikawa, Nakamori, Takenaka, Aoki, Yamazaki, Hashiguchi, Takashima and Maruyama.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Int J Mol Sci. 2022 Jun 27;23(13):
pubmed: 35806149
Am J Med Genet A. 2014 May;164A(5):1180-7
pubmed: 24664533
Front Neurol. 2021 Oct 12;12:694966
pubmed: 34712195
Prog Lipid Res. 2021 Jul;83:101116
pubmed: 34293403
Rev Endocr Metab Disord. 2018 Mar;19(1):93-106
pubmed: 29926323
AJNR Am J Neuroradiol. 2000 May;21(5):839-44
pubmed: 10815658
Baillieres Clin Endocrinol Metab. 1990 Sep;4(3):561-82
pubmed: 2268228
Rinsho Shinkeigaku. 2017 Feb 25;57(2):82-87
pubmed: 28132977
Mol Genet Metab Rep. 2015 Nov 06;5:80-84
pubmed: 28649548
JIMD Rep. 2018;38:101-105
pubmed: 28685493
Mol Genet Metab. 2022 Sep-Oct;137(1-2):213-222
pubmed: 36155185
J Inherit Metab Dis. 2022 Jul;45(4):804-818
pubmed: 35383965
J Neurochem. 2017 Feb;140(3):435-450
pubmed: 27861899
Curr Genet Med Rep. 2017 Sep;5(3):132-142
pubmed: 29177110
Chin Med J (Engl). 2020 Jun 5;133(11):1358-1360
pubmed: 32515919
Ther Adv Neurol Disord. 2019 Apr 22;12:1756286419843359
pubmed: 31040882
Proc Natl Acad Sci U S A. 2018 Jul 3;115(27):7039-7044
pubmed: 29915090
Biochimie. 2014 Mar;98:135-42
pubmed: 24316281
J Inherit Metab Dis. 2021 Jul;44(4):893-902
pubmed: 33638202
Mol Genet Metab. 2009 Dec;98(4):372-7
pubmed: 19699128
Open Biol. 2017 May;7(5):
pubmed: 28566300

Auteurs

Ruoyi Ishikawa (R)

Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.

Masahiro Nakamori (M)

Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.

Megumi Takenaka (M)

Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.

Shiro Aoki (S)

Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.

Yu Yamazaki (Y)

Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.

Akihiro Hashiguchi (A)

Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.

Hiroshi Takashima (H)

Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.

Hirofumi Maruyama (H)

Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.

Classifications MeSH